Dr. Zandberg on Durvalumab Trial in Head and Neck Cancer
September 22nd 2017Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Read More